Relief (and some regret) as EU scales back swaps transparency

Leaked document outlines plans to narrow scope of dysfunctional OTC disclosure regime

The European Union’s transparency rules for over-the-counter derivatives are widely seen as a failure, with endless problems blighting a regime that was meant to cast a new light on a notoriously opaque and complex market.

Quentin van Lidth, director of regulatory and public affairs at BNP Paribas, sums up the industry’s feeling in a single sentence: “Today, we’ve got post-trade transparency with huge scope and too much information, which is not helping anyone.”

The complaints sent regulators

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here